Net profit of Pfizer declined 28.57% to Rs 57.17 crore in the quarter ended June 2017 as against Rs 80.04 crore during the previous quarter ended June 2016. Sales declined 16.02% to Rs 420.91 crore in the quarter ended June 2017 as against Rs 501.23 crore during the previous quarter ended June 2016.

Powered by Capital Market - Live News

Pfizer announced that dividend, if approved by the members at the ensuing Annual General Meeting will be paid on 14 September 2017.

Powered by Capital Market - Live News

Pfizer will hold a meeting of the Board of Directors of the Company on 29 July 2017.

Powered by Capital Market - Live News

The announcement was made after market hours yesterday, 31 May 2017.

Meanwhile, the S&P BSE Sensex was up 3.43 points or 0.01% at 31,149.23. The S&P BSE Mid-Cap index was up 33.54 points, or 0.23% at 14,669.36.

On the BSE, 3,174 shares were traded on the counter so far as against the average daily volumes of 5,219 shares in the past one quarter. The stock had hit a high of Rs 1,785.80 and a low of Rs 1,697 so far during the day. The stock had hit a 52-week high of Rs 2,055 on 9 September 2016. The stock had hit a 52-week low of Rs 1,641 on 30 May 2017.

The mid-cap company has equity capital of Rs 45.75 crore. Face value per share is Rs 10.

Pfizer announced that it has entered into an acquisition agreement with AstraZeneca AB, Sweden (AstraZeneca), pursuant to which the brand Neksium is being acquired by the company in India for a consideration of Rs 75 crore. Neksium (esomeprazole) complements the company's existing product portfolio in the gastrointestinal (GI) therapeutic area, Pfizer said.

Pfizer's net profit dropped 21.98% to Rs 68.04 crore on 14.52% fall in net sales to Rs 438.06 crore in Q4 March 2017 over Q4 March 2016.

Pfizer is a leading biopharmaceutical company.

Powered by Capital Market - Live News